Summary & Overview
HCPCS G9222: Pneumocystis jiroveci Pneumonia Prophylaxis, Low CD4
HCPCS Level II code G9222 documents prescription of prophylaxis against Pneumocystis jiroveci pneumonia within three months of a CD4+ cell count falling below 200 cells/mm3. The code captures a clinically important preventive intervention for patients with advanced immunosuppression, routinely relevant in HIV care and other conditions causing severe CD4+ depletion. Nationally, accurate capture of this service affects quality measurement, care coordination, and preventive care benchmarks for vulnerable patient populations.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, the clinical context for prophylaxis initiation, and what to expect in coverage and billing practice. The publication covers typical sites of service, common uses of the code in outpatient management, and how the code aligns with quality reporting for opportunistic infection prevention. Where input data is incomplete, the report flags missing fields: Data not available in the input. The goal is to give billing staff, practice managers, and policy analysts a clear, nationally oriented summary of HCPCS Level II code G9222 and its role in documenting Pneumocystis jiroveci pneumonia prophylaxis.
Billing Code Overview
HCPCS Level II code G9222 indicates Pneumocystis jiroveci pneumonia prophylaxis prescribed within 3 months of low CD4+ cell count below 200 cells/mm3. This service represents initiation or documentation of prophylactic therapy intended to prevent Pneumocystis jiroveci pneumonia in patients with significant CD4+ immunosuppression.
-
Service type: Prophylactic medication management and prescription for opportunistic infection prevention
-
Typical site of service: Outpatient ambulatory clinic or primary care/infectious disease clinic where HIV or immunocompromised patients receive longitudinal care
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 34-year-old patient with known HIV infection presents for routine follow-up after recent laboratory testing. Their CD4+ T-lymphocyte count returns at 150 cells/mm3. The HIV clinic nurse schedules a same-day visit with the infectious disease clinician or HIV specialist to review results and prescribe prophylaxis for Pneumocystis jiroveci pneumonia (PJP). The clinician documents history, reviews antiretroviral therapy adherence and drug interactions, assesses allergy history, and selects an appropriate prophylactic agent (commonly trimethoprim-sulfamethoxazole). A prescription is provided and coded for PJP prophylaxis initiation within three months of documented CD4+ count below 200 cells/mm3. Pharmacy dispensing or medication counseling may occur in the clinic or at an outpatient pharmacy. Typical workflow steps: laboratory result triggers clinician notification → outpatient visit or telehealth encounter for medication management → prescription issued and documented with indication of CD4 count and timing → medication dispensed and follow-up arranged for tolerance and adherence monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the day of a procedure | Use when an E/M visit on the same day documents a separate evaluation beyond medication management for PJP prophylaxis |